Canary Capital Launches Staked Injective ETF (INJC)

Canary Capital launched the Canary Staked INJ ETF (INJC) on the Nasdaq, offering U.S. investors direct exposure to Injective (INJ) alongside blockchain staking rewards through traditional brokerage accounts. The ETF would hold INJ directly, with BitGo serving as custodian, and aims to stake at least 90% of its token holdings under normal market conditions. Staking rewards would generally be reinvested and reflected in the fund's daily net asset value. INJC proposes a 1.10% annual sponsor fee, alongside a separate charge equal to 30% of staking rewards. The Injective Foundation has indicated plans to purchase up to $15 million in seed shares, potentially providing initial capital for the fund. The launch remains subject to the effectiveness of its securities registration.